KAMADA » INVESTORS

INVESTMENT HIGHLIGHTS

LATEST NEWS

Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT

Jul. 10, 2018

Kamada announced that it has received positive scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the development plan for its proposed pivotal Phase 3 study for its proprietary Inhaled Alpha-1 Antitrypsin therapy (Inhaled AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD).

50 years since the first use of Anti-D immunoglobulin

Jul. 1, 2018

Since 1967, the lives of countless babies have been saved by the pioneering Rh Program - and to date, millions of doses of anti-D have been given to Rh negative women.

More News

FINANCIAL REPORTS

Q1 / 2018 Financial Report

Jul. 15, 2018

XBRL Annual Reports 2017

Dec. 31, 2017

Annual Report 2017

Dec. 30, 2017

More Reports

STOCK QUOTE

NASDAQ

KMDA:$0
Change:0.00%
Date & Time:
For more information: KAMADA on NASDAQ website

TASE

Share price                                             Daily volume(NIS)                

Click here for more information 

 Convertible bond                                  Daily volume(NIS)

Click here for more information

 For more information: KAMADA on Tel- Aviv Stock Exchange website

CORPORATE GOVERNANCE

Please click "Read more" to view Kamada's Corporate Governance items.

Read more

IR CONTACT & FAQ

Chaime Orlev,
CFO
ir@kamada.com

Bob Yedid
LifeSci Advisors
646-597-6989
bob@lifesciadvisors.com

 

Read more